EcoDrugPlus

Plasminogen-Like

Ensembl ID : ENSSTUG00000015531
Gene Symbol: LOC115174819
3 Cross references
250 Possible Orthologues:

Platelet Activating Factor Receptor

Ensembl ID : ENSSTUG00000016032
Gene Symbol: PTAFR
1 Cross references
215 Possible Orthologues:

Platelet Activating Factor Receptor

Ensembl ID : ENSSTUG00000021643
Gene Symbol: PTAFR
3 Cross references
209 Possible Orthologues:

Platelet-Activating Factor Acetylhydrolase-Like

Ensembl ID : ENSSTUG00000049730
Gene Symbol: LOC115174547
3 Cross references
197 Possible Orthologues:

Platelet-Derived Growth Factor Receptor Alpha-Like

Ensembl ID : ENSSTUG00000008915
Gene Symbol: LOC115158529
3 Cross references
198 Possible Orthologues:

Platelet-Derived Growth Factor Receptor Alpha-Like

Ensembl ID : ENSSTUG00000003608
Gene Symbol: LOC115192386
3 Cross references
197 Possible Orthologues:

Platelet-Derived Growth Factor Receptor Beta-Like

Ensembl ID : ENSSTUG00000039175
Gene Symbol: LOC115154887
2 Cross references
174 Possible Orthologues:

Platelet-Derived Growth Factor Receptor Beta-Like

Ensembl ID : ENSSTUG00000006606
Gene Symbol: LOC115174164
3 Cross references
192 Possible Orthologues:

Platelet-Derived Growth Factor Receptor Beta-Like

Ensembl ID : ENSSTUG00000003118
Gene Symbol: LOC115205391
3 Cross references
192 Possible Orthologues:

Polo Like Kinase 1

Ensembl ID : ENSSTUG00000019860
Gene Symbol: PLK1
3 Cross references
188 Possible Orthologues:

Poly(Adp-Ribose) Polymerase 1

Ensembl ID : ENSSTUG00000026695
Gene Symbol: PARP1
3 Cross references
207 Possible Orthologues:

Poly(Adp-Ribose) Polymerase 2

Ensembl ID : ENSSTUG00000007279
Gene Symbol: PARP2
3 Cross references
185 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).